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Inhibitory Effects of ab initio Antiviral Peptides Efficiently 
Designed Based on the APD3 Database
Thomas Ripperda Jr, Yangsheng Yu, Atul Verma, St. Patrick Reid, Guangshun Wang
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
Natural antimicrobial peptides (AMPs) aid in many organisms innate 
immune defense against pathogens. Engineering new therapeutics from 
natural AMP templates may provide an effective treatment to viral infections 
such as SARS CoV-2 and Ebola, and drug-resistant bacteria. One way to 
design antimicrobial peptides is the database filtering technology (DFT). 
The DFT is an ab initio design that selects the most probable parameters 
for an AMP by statistical analysis in the antimicrobial peptide database 
(APD3)1. To our knowledge, however, the DFT design has never been used 
to develop an antiviral peptide. The improved DFT proposed provides a 
faster and simpler design for peptides. 
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Table 1:Cytotoxicity in three different cell lines for DFTavP3 and DDIP1.
Table 2: Simultaneous antimicrobial and stability assay of designed 









t Cell Only Virus DFTavP3 DDIP1 LL-37
Figure 3: Infection flow cytometer graphs of DFTavP3,  DDIP1, LL-37 peptides at 5 µM 
concentration (A). Inhibition of DFTavP3, DDIP1, LL-37 peptides at 2.5, 5 and 10µM 
concentrations (B). Prevention of SARS-CoV-2 infection (C).
❑The improved DFT resulted in a faster and simpler design 
method for designing antimicrobial peptides.
❑DFTavP3 resulted in viral inhibition but was highly cytotoxic and 
unstable. DDIP1 was also found to be inhibitory against viral 
infections including SARS-CoV-2 and was stable and 
noncytotoxic.
❑DFTavP series viral inhibition results demonstrated lengths 
closer to the most probable length of 20-30 amino acids had 
better inhibition.
In Vitro Viral Assay
A prevention and treatment antiviral assay was conducted for DDIP1, 
iDFT antiviral peptide 3 (DFTavP3),  and LL-37 using Ebola pseudoviral 
system and SARS-CoV-2. LL-37 acted as a positive control. 
Peptide Sequences
Peptide Design Tool
The APD3 works on classifying natural AMPs 
so that statistical analysis can occur. The APD3 
contains 3273 natural AMPs (193 antiviral 
peptides) from 3 domains and 6 kingdoms and 
provides a multitude of search functions and 
tools to analyze the peptides2.
A B C
D
Figure 1: The DFT design (A) compared to the iDFT design (B), the amino acid 
frequency for 11- 20 residue antiviral peptides (C), and amino acid frequency of 19 Θ
defensins in the APD3 (D). 




aHC50 is the 50% hemolytic concentration in human red blood cells. bThe animal HC50 was conducted on mouse 
red blood cells. cTC50 is the 50% cytotoxic concentration in a HaCa cell line.  
Figure 4: Inhibition of Ebola pseudo-virus after time dependent treatment for 











Figure 2: Infection flow cytometer graphs of DFTavP series at 10 µM concentration (A). 

























DFTavP3 <12.5 <10 25
DDIP1 >160 >160 >100
B
Method for Database Designed and Improved Peptide (DDIP1)
DDIP1 was designed using the database-aided design3. It was modified 
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